JATT Acquisition (NYSE:JATT – Get Rating) and Novavax (NASDAQ:NVAX – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, risk, profitability and earnings.

Institutional & Insider Ownership

44.8% of JATT Acquisition shares are owned by institutional investors. Comparatively, 42.6% of Novavax shares are owned by institutional investors. 2.1% of Novavax shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares JATT Acquisition and Novavax's net margins, return on equity and return on assets.

Earnings & Valuation

JATT Acquisition has higher earnings, but lower revenue than Novavax.

Analyst Ratings

This is a summary of current ratings for JATT Acquisition and Novavax, as reported by MarketBeat.com.

Novavax has a consensus price target of $128.25, indicating a potential upside of 510.71%. Given Novavax's higher possible upside, analysts plainly believe Novavax is more favorable than JATT Acquisition.

Summary

JATT Acquisition beats Novavax on 5 of the 9 factors compared between the two stocks.

About JATT Acquisition

(Get Rating)

JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.

About Novavax

(Get Rating)

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Receive News & Ratings for JATT Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for JATT Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.